Clinical trials: Transmission
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding.
- Trial name
- NCT00002373
- Testing
- Maribavir
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus, HIV Infections
Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)
The purpose of the study is to evaluate the bioequivalence between Fixed-dose Combination (FDC) tablet formulation of Dolutegravir (DTG) 50 milligrams (mg) and Rilpivirine (RPV) 25 mg versus co-administration of the separate…
- Trial name
- NCT02741557
- Testing
- DTG, RPV, DTG/RPV FDC
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Papillomavirus Infections
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
The present study is a multicenter, open, non-interventional, prospective observational clinical study for the evaluation of the effectiveness of Papilocare® (medical device with CE mark) in the regression of cervix cytological…
- Trial name
- PAPILOBSGR (NCT06399341)
- Testing
- Papilocare vaginal gel
- Where
- 4 sites in Greece
- Volunteers
- 524 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
HIV Infection
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA…
- Trial name
- HEAT (NCT00244712)
- Testing
- emtricitabine/tenofovir, abacavir/lamivudine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age.
- Trial name
- NCT05285826
- Testing
- 9vHPV Vaccine
- Where
- 34 sites in China
- Volunteers
- 8,100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
- Trial name
- NCT00126880
- Testing
- AVX754, 3TC
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Avexa
Chronic Hepatitis C, Human Immunodeficiency Virus
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.
- Trial name
- NCT01783678
- Testing
- Sofosbuvir, RBV
- Where
- 24 sites in Australia, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
Mycoses, HIV Infections
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts < 250 cells/mm3 who are…
- Conditions
- Mycoses, HIV Infections, Coccidioidomycosis
- Trial name
- NCT00002325
- Testing
- Fluconazole
- Where
- 3 sites in United States
- Sponsor
- Pfizer
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.
HIV Infections
A Study of 1592U89 in HIV-Infected Children
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available.
- Trial name
- NCT00002197
- Testing
- Abacavir sulfate
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Glaxo Wellcome
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
HIV Infections
A Study of DPC 817 in HIV-Infected Males
The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
- Trial name
- NCT00040274
- Testing
- DPC 817
- Where
- 2 sites in United States, Germany
- Volunteers
- 30 people
- Sponsor
- Pharmasset
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HIV Infection
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
The purpose of this study is to monitor adverse events in HIV-infected children <18 years old who are exposed to Atazanavir in a real-world setting in Europe.
- Trial name
- NCT01389310
- Where
- 9 sites in Belgium, Germany and 5 more
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
Acquired Immunodeficiency Syndrome
Dimiracetam in Painful Neuropathies Affecting AIDS Patients
The purpose of this study is to assess the efficacy and tolerability of orally administered dimiracetam for 10 weeks to AIDS patients under treatment with antiretroviral agents presenting a disease and /or treatment related…
- Trial name
- DIPANAP (NCT01444690)
- Testing
- Dimiracetam, Dimiracetam 25 mg
- Where
- Switzerland
- Volunteers
- 244 people
- Sponsor
- Neurotune AG
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
- Trial name
- NCT02467335
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter…
- Trial name
- NCT05418868
- Testing
- Cabotegravir 200 mg/mL, Cabotegravir >=400 mg/mL, Cabotegravir Formulation I
- Where
- 3 sites in United States
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Acquired Immune Deficiency Syndrome
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
- Trial name
- NCT00055185
- Testing
- CD4-IgG2 (PRO 542)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.